Green Cross, aRigen under joint research to combat superbacteria

Published: 2011-01-26 06:56:00

Updated: 2011-01-26 06:56:00

Green Cross Corp. said Friday that it has signed an exclusive license with aRigen Pharmaceuticals in Japan to develop and commercialize WAP-8294A2 (Lotilibcin), a first-line anti-MRSA (methicillin-resistant Staphylococcus aureus) product candidate, possibly in 2016 in Korea.

The agreement between aRigen and GCC is the first joint antibiotic development program by a leading Japanese biotech a...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.